CDMO for Drug Development, Contract Development and Manufacturing Organizations, commonly referred to as CDMOs, are the infrastructure on which a significant and growing share of the global pharmaceutical pipeline depends. The majority of drug candidates in development today, whether they originate from large pharmaceutical companies, mid-sized specialty pharma organizations, or emerging biotechnology companies, will spend some portion of their development journey in the hands of a CDMO. Understanding what a CDMO is, what it does, and how to evaluate the ones available to your program is foundational knowledge for anyone making drug development decisions.
The choice of CDMO partner is not a procurement decision. It is a scientific and strategic decision with consequences that extend across years of development work, regulatory interactions, and ultimately the quality and reliability of the drug product that reaches patients. Organizations that treat CDMO selection as a vendor sourcing exercise rather than a partnership selection process consistently find that the limitations of this approach surface at the worst possible moments in a development program.
This article provides a clear-eyed explanation of what CDMOs are, how the CDMO market is structured, what services fall within the CDMO scope, and the criteria that should guide the selection of a CDMO partner for a pharmaceutical or biopharmaceutical development program.
Defining the CDMO: What the Category Actually Covers
A Contract Development and Manufacturing Organization provides pharmaceutical development services and GMP manufacturing to drug sponsors on a contractual basis. The CDMO model exists because most pharmaceutical and biotechnology companies, including many large ones, find it more efficient to outsource specific development and manufacturing functions to specialized organizations than to build and maintain all required capabilities internally.
The term CDMO encompasses a wide range of organizational profiles, from large multinational contract manufacturers with dozens of facilities and billions of dollars in revenue to specialized organizations focused on a narrow set of technologies or a specific phase of development. Understanding where a specific CDMO sits in this spectrum, what its genuine areas of scientific depth are, and what aspects of your program it is best positioned to support is the starting point for any meaningful evaluation.
The distinction between a CRO and a CDMO is worth clarifying because the terms are sometimes used imprecisely. A Contract Research Organization, or CRO, typically provides testing, analytical, and research services but does not produce drug substance or drug product for clinical use. A CDMO provides development services and GMP manufacturing of drug substance or drug product. Many organizations provide both CRO-type testing services and CDMO-type development and manufacturing services, and Quality Chemical Laboratories is an example of this integrated model, providing analytical testing, development services, and clinical trial material manufacturing within a single FDA-registered organization.
The integration of CRO and CDMO functions within a single organization is increasingly valued by drug sponsors because it eliminates the coordination burden between separate analytical and manufacturing organizations, provides continuity of scientific knowledge across the development-to-manufacturing transition, and creates a single point of accountability for program outcomes rather than distributing responsibility across multiple vendors.
The Services a CDMO Provides Across the Development Lifecycle
The scope of services that a full-service CDMO provides spans from the earliest stages of pre-clinical development through commercial manufacturing, and the depth of coverage in each area varies significantly between organizations. Understanding what your program needs at each stage of development and matching those needs to a CDMO’s genuine capabilities is the analytical framework for a sound selection decision.
In the pre-clinical and early development phase, CDMO services typically include drug substance characterization, pre-formulation studies, early-stage analytical method development, and the production of non-GMP materials for toxicology and pharmacology studies. This work establishes the physicochemical and biopharmaceutical property profile of the drug substance that will inform every subsequent formulation and manufacturing decision. Organizations that underinvest in this early characterization work typically discover the consequences during later-stage development when the gaps in understanding about the drug substance create unexpected complications.
Clinical development phase services encompass formulation development, analytical method development and validation, GMP manufacturing of clinical trial materials, packaging and labeling for clinical supply, stability storage and testing, and the quality system documentation that regulatory submissions require. The GMP manufacturing component is the most visible CDMO function during this phase, but the quality of the analytical and formulation science underlying the manufactured materials is what determines whether the clinical supply performs as designed and whether the regulatory package generated during this phase will survive agency review.
Late-stage and commercial manufacturing services include process scale-up, technology transfer to commercial manufacturing scale, validation activities required for regulatory approval, and commercial supply operations. Not all CDMOs operate across the full development-to-commercial spectrum. Some specialize in early-phase clinical supply and do not have commercial manufacturing infrastructure. Others focus on commercial manufacturing and are not well positioned for the flexible, science-driven work of early-phase development. Understanding where a CDMO’s capabilities are strongest relative to your program’s current and anticipated needs is essential to making a selection that will serve the program over time.
How the CDMO Market Is Organized: Size, Specialization, and Scope
The global CDMO market is large, fragmented, and highly varied in the type of value different organizations provide. The largest CDMOs operate across multiple continents, serve hundreds of clients simultaneously, and maintain capabilities across essentially the full range of pharmaceutical dosage forms and biologics. Their scale provides access to capabilities that smaller organizations cannot replicate, but it also means that individual programs may receive less scientific attention and less organizational priority than they would at a smaller, more focused partner.
Mid-size CDMOs occupy a range of positions in the market, from organizations that have grown their specialized capabilities to a scale that supports a large client base to organizations that remain deliberately focused on a specific therapeutic category, dosage form technology, or development phase. These organizations often represent the best combination of scientific depth and client attention for programs that fit their specific areas of expertise.
Small and specialized CDMOs, including organizations focused on specific technologies such as lyophilization, modified release formulations, or biologic drug products, provide the deepest scientific expertise within their defined scope. For programs with specific technical requirements that align with a specialist’s core capabilities, these organizations can provide a quality of scientific engagement that generalist organizations do not match. The limitation is that their scope is narrower, which may require engaging multiple vendors to cover the full development program.
The geographic dimension of CDMO selection has become more complex in recent years as drug sponsors have become more attentive to supply chain resilience. The concentration of pharmaceutical manufacturing in certain regions, and the supply disruptions that have accompanied global logistical challenges, have elevated the value of domestic CDMO capabilities for programs where supply reliability is a critical consideration. For United States-based drug sponsors, the availability of high-quality CDMO partners with domestic facilities and established regulatory relationships with the FDA is increasingly a selection criterion alongside scientific capability and cost.
The Criteria That Actually Matter in CDMO Selection
The evaluation criteria that matter most in CDMO selection depend in part on the characteristics of the specific program, but several criteria are broadly applicable across programs and program stages.
Regulatory track record is the most objective indicator of a CDMO’s quality system performance and its ability to produce work that satisfies agency expectations. FDA inspection history, including the absence of warning letters and the nature of any observations from completed inspections, provides a verifiable record of how the organization has performed under regulatory scrutiny. A CDMO with a strong FDA inspection history has demonstrated that its quality systems function as designed under the pressure of agency oversight, which is the most relevant test of quality system robustness available.
Scientific depth in the relevant capability areas is the criterion that most directly affects the quality of the scientific work your program will receive. A CDMO that lists a capability in its marketing materials is not necessarily a CDMO with genuine scientific expertise in that area. Evaluating scientific depth requires going beyond the capabilities overview to understand the qualifications and experience of the scientists who will actually work on the program, the instrumentation available to support the work, and the track record of the organization in delivering successful outcomes in the specific capability area you need.
Communication and responsiveness during the evaluation process are reliable leading indicators of how the organization will communicate during the program. A CDMO that is slow to respond to queries during the selection process, that provides vague or generic answers to specific technical questions, or that escalates client interactions to business development staff rather than scientists is signaling the client experience that program sponsors should expect throughout the engagement. Conversely, a CDMO that engages directly, responds promptly, and provides technically grounded answers to detailed questions is demonstrating the organizational culture that makes a development partnership genuinely productive.
Integration of capabilities is increasingly a differentiating criterion as drug sponsors recognize the cost and risk of managing multiple vendors across a development program. A CDMO that can support analytical testing, formulation development, stability management, and clinical trial material manufacturing within a single quality system, under a single FDA registration, and with a scientific team that communicates across functions, provides a fundamentally different program experience than a collection of separate vendors each managing their defined scope independently.
What to Ask When Evaluating a CDMO
The questions that reveal the most about a CDMO’s genuine capabilities and organizational culture are typically the ones that require specific, substantive answers rather than general descriptions of capability.
Asking about specific experience with your drug substance class, your proposed dosage form, and your development phase produces answers that differentiate organizations with genuine depth from those representing capabilities they have in theory but not in practice. A CDMO with real experience in your specific technical area can discuss specific challenges they have encountered, how they resolved them, and what they learned. One that represents experience it does not have will provide general answers that do not engage with the specifics of your question.
Asking about the quality system and how deviations and out-of-specification results are handled reveals the organizational approach to quality far more effectively than reviewing a quality manual. The answer to this question should describe a system that is responsive, transparent, and focused on root cause understanding rather than one that is primarily focused on documentation compliance.
Asking about how the organization handles capacity constraints and competing client priorities reveals the client experience in practical terms. Every CDMO has periods of high demand, and how the organization manages client priorities during those periods is what determines whether your program is protected or deprioritized when schedule pressure is highest.
QCL as a CDMO Partner: What the Organization Offers and How It Approaches the Partnership
Quality Chemical Laboratories has operated as an integrated CRO and CDMO since its founding in 1998, providing analytical testing, development services, and clinical trial material manufacturing from its FDA-registered campus in Wilmington, North Carolina. The organization’s development over more than 25 years, from a raw material testing laboratory to a full-service CDMO with sterile manufacturing capabilities, reflects a consistent strategy of building scientific depth in areas that matter to the pharmaceutical and biopharmaceutical clients it serves.
QCL’s analytical capabilities span raw material testing, analytical development and validation, drug product analysis and stability services, biopharmaceutical services, microbiology laboratory services, and impurity analysis. These capabilities are integrated with QCL’s formulation development and GMP manufacturing operations within a single organizational structure and a single quality system, providing the continuity of scientific knowledge and the unified accountability that the most effective development partnerships require.
QCL’s approach to client relationships, treating sponsors as partners and taking ownership of program challenges rather than managing them at arm’s length, is the cultural foundation that makes the difference between a vendor relationship and a development partnership.
To learn more about QCL’s capabilities or to discuss your specific program requirements, contact the business development team at businessdev@qualitychemlabs.com or call (910) 796-3441. You can also request a quote here. QCL’s laboratories are located in Wilmington, North Carolina, and the team welcomes visits from prospective partners by appointment.